~~<i id='790BA30F4C'><strike id='790BA30F4C'><tt id='790BA30F4C'><pre id='790BA30F4C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

Wikipedia

author：hotspot 2025-09-29 18:15:30 - browse：813

Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.

Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.

This is a familiar but tiring refrain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Medicare drug price negotiation continues, as pharma counteroffers

explore

knowledge

focus

knowledge

focus

AdobeAtfirstglance,theCoalitionforHealthAIlookslikeanytechnologylobbyinggroup.Itsmembership—includin

WSS

Gene therapy has helped boys walk. Can scientists keep it that way?

Death of patient in Alzheimer’s trial raises question of possible risks

Harvard's David Sinclair gets blowback over aging

New guidelines on severe brain injury complicate already difficult decisions

He's 19 months old and has one of the world’s rarest diseases

Change Healthcare: What is it, why does its cyberattack matter?

explore

Wikipedia

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

In areas with more Black doctors, Black people live longer

Medicare details structure of new drug price negotiation program

Why we need to separate burnout from moral injury in health care

Heart attack and stroke risk calculators need revising

State of the Union pitch: Bigger Medicare drug price negotiations

The cancer drug shortage isn’t new — and neither are the solutions

Medicare drug price negotiation continues, as pharma counteroffers

Walensky prepares to leave CDC — and Congress — behind

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

knowledge

Lack of health data on LGBTQ+ people has serious consequences

A new approach to psychiatric drug development

Why Talkspace is targeting Medicare, a tricky market

Harvard's David Sinclair gets blowback over aging

Florida health officials providing scant details on measles cases

CDC concerned about possible undetected monkeypox spread in U.K.

knowledge

focus

knowledge

focus